Biomillenia and QIAGEN will give a presentation on this joint achievement at the 3 rd Annual European Microbiome Congress in London. The presentation will highlight how Biomillenia can culture and screen magnitudes more live bacterial species than with common microbiology methods directly from natural samples, such as from human skin microbiota.About Biomillenia Biomillenia harnesses smart microbes to restore the body's healthy balance and help prevent lifestyle diseases. Using its proprietary technology platform, the company is able to isolate strains of beneficial microbes based on their functional traits at speeds and in volumes that to date have not been feasible. Biomillenia's core strategy is to incorporate these smart microbes into consumer products targeting skin, women & infant, immune and digestive health. Biomillenia also offers its smart microbe platform to leading industry players to replace traditional chemicals in agricultural and animal health products. The company was founded on research emanating from the laboratories of its scientific founders at the Broad Institute, Harvard University and École Supérieure de Chimie Industrielles de Paris (ESPCI). The company is based in Paris, France.
Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) for use of QIAGEN's Microbial Genomics Pro Suite to generate next generation sequence data on microbes identified using Biomillenia's proprietary microbiome-on-a-chip technology. Biomillenia's approach is able to identify strains of microbes previously deemed unculturable, and at unprecedented speeds. "The inability to culture, screen and isolate live bacterial species directly from the rich diversity of microbiota has previously been a significant limitation in research and product development. The combination of our microbiome-on-a-chip technology with QIAGEN's industry-leading microbial genomics bioinformatics platform provides a complete and effective solution to this challenge," said Dirk Loeffert, Ph.D., CEO of Biomillenia. Biomillenia has developed a proprietary droplet-based microfluidics chip platform that cultures bacterial species directly from natural samples at the single cells level. This microbiome-on-a-chip technology contains greater than 100 million parallel picoliter-size droplet, allowing for a much higher diversity of live bacterial species that grow to clonal populations than standard microbiology methods. Additionally, these picoliter scale cultures can be isolated drop by drop based on phenotypic selection by a broad range of assay capabilities, effectively enabling selection of novel bacterial strains with desired traits directly from original samples. Biomillenia is able to screen up to 100 million microbes in parallel in a 2 milliliter reaction in 3 days whereas traditional culture methods would take 3 years in 10,000 liter reaction volume. QIAGEN's bioinformatics platform provides an easy-to-run infrastructure for analysing microbial genomes, from sequence assembly to microbe identification. "QIAGEN has developed Microbial Genomics Pro Suite to make state-of-the-art bioinformatics reliable and accessible for researchers that need to analyse and visualize microbial genomes and microbiomes. Biomillenia has demonstrated an exciting new application for our powerful microbial bioinformatics. We are very pleased to have been able to reduce the time and costs in developing the required informatics pipelines and thereby enable significant acceleration in the development of their exciting Microbiome-on-a-chip technology," said Dr. Frank Schacherer, Vice President, Head of Products and Solutions, at QIAGEN Bioinformatics.